$ATNM·4

Actinium Pharmaceuticals, Inc. · Mar 16, 6:18 PM ET

Actinium Pharmaceuticals, Inc. 4

4 · Actinium Pharmaceuticals, Inc. · Filed Mar 16, 2017

Insider Transaction Report

Form 4
Period: 2017-03-14
DAVE KAUSHIK J
DirectorPresident and CEO
Transactions
  • Award

    Options to purchase common stock

    2017-03-14$1.39/sh+250,000$347,500250,000 total
    Exercise: $1.39Exp: 2027-03-14Common Stock (250,000 underlying)
Footnotes (1)
  • [F1]Pursuant to the terms of the company's Amended and Restated 2013 Stock Plan, 2% of the options shall vest each month from the date of grant. In addition, 100,000 options are subject to cancellation based on the obtainment of certain milestones.

Documents

1 file
  • 4
    f4031417dave_actinium.xmlPrimary

    OWNERSHIP DOCUMENT